

The Valens Company

07:55 08 Apr 2020

The Valens Company begins making hand sanitizer to help combat coronavirus pandemic

The Valens Company (CVE:VLNS) (OTCQX:VLNCF), a manufacturer of cannabinoid-based products, said Wednesday that it will begin making hand sanitizer to help alleviate product supply shortages as a result of the coronavirus (COVID-19) health crisis.

In a statement, the Kelowna-based company said it plans to start with an initial 1,300 litre-batch at its facility.

The group said it will bottle and donate 40,000 bottles of hand sanitizer in various formats to frontline health care workers across Canada. The company is focusing on British Columbia, Alberta and Ontario for distribution, as well as providing 10,000 units to Shoppers Drug Mart to aid their public-facing workers at pharmacies across Canada.

READ: The Valens Company gets go-ahead to list its shares on the Toronto Stock Exchange

Simultaneously, the company said, it is working with hospital networks, all essential services and various associations servicing the vulnerable, to distribute supplies to those who need it most.

In a statement, Valens' CEO Tyler Robson explained that the firm considered it their "corporate responsibility" to leverage its existing extraction and production capabilities to distribute products that have the "potential to fight the transmission" of the virus.

"We at The Valens Company recognize the urgency in assisting our communities across the country during this critical phase of the COVID-19 pandemic," Robson said.

"We are quickly mobilizing our teams and resources to alleviate essential supply shortages and contribute as much as we can to those selflessly helping on the frontlines," he added.

Valens has also donated significant quantities of various personal protective equipment (PPE) such as gloves, gowns, and sanitizing wipes from the company's existing supply. The group is also expecting a second shipment of PPE gear, including masks, which will also be donated to healthcare workers and people who are working on the front lines of the coronavirus pandemic.

Price target hiked by Canaccord

Separately, Canaccord Genuity analyst Kimberley Hedlin continues to rate Valens Groworks a Speculative Buy. She boosted her share target price to \$8.25 from \$7.25 (current share price is at around \$2.31).

According to Hedlin, the spread of the coronavirus has created "heightened risks surrounding supply chains, consumer

Price: 2.39

Market Cap: \$305.23 m

1 Year Share Price Graph



Share Information

Code: VLNS

Listing: TSX

52 week	High	Low
	3.13	1.94

Sector: Cannabis

Website: thevalenscompany.com

Company Synopsis:

The Valens Company is a multi-licensed, vertically-integrated cannabis company focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white-label product development.

action@proactiveinvestors.com

demand, distribution and B2B sales" that are likely to weigh on Canadian cannabis companies.

However, she said: "For the time being, it is somewhat business as usual for Canadian cannabis companies, most of which have indicated they are increasing sanitation and distancing efforts. With the exception of NL, PEI and ON, cannabis retailers remain open in Canada, although some retailers have made the decision to close, reduce hours or move to click and collect models."

She added: "For both LPs and retailers, staffing disruptions have occurred due to employees staying home due to minor illness or needing to care for children. Since the outbreak escalated in early March, LPs and retailers have reported an uptick in sales. [Many US] states have now started to see a decline in sales."

Previously named Valens Groworks, the firm announced a rebranding to 'The Valens Company' in December last year to reflect the fact it isn't really a cannabis cultivator. It is one of Canada's most profitable producers of cannabis products, medical and recreational, and it is scaling up operations.

— Adds analyst comments, price target hike —

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of The Valens Company named herein, including the promotion by the Company of The Valens Company in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).